This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reata Pharmaceuticals Future Growth

Future criteria checks 5/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Reata Pharmaceuticals.

Key information

62.0%

Earnings growth rate

61.0%

EPS growth rate

Pharmaceuticals earnings growth	23.9%
Revenue growth rate	48.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	26 Sep 2023

Recent future growth updates

Recent updates

Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

May 10

FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug

Oct 13

Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?

Oct 12

Reata Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth

Jun 22

Reata Pharmaceuticals: Once Beaten, Twice Shy

Mar 28

Reata's Advisory Committee Hiccup Ruins Its Future Prospects

Dec 31

Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Dec 23

Earnings and Revenue Growth Forecasts

NasdaqGM:RETA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	704	201	116	N/A	6
12/31/2024	379	-149	-67	N/A	8
12/31/2023	89	-99	-265	N/A	5
6/30/2023	23	-88	-249	-248	N/A
3/31/2023	1	-354	-231	-228	N/A
12/31/2022	2	-312	-208	-204	N/A
9/30/2022	3	-312	-280	-277	N/A
6/30/2022	10	-305	-276	-272	N/A
3/31/2022	11	-304	-250	-249	N/A
12/31/2021	11	-297	-237	-236	N/A
9/30/2021	14	-278	-159	-158	N/A
6/30/2021	8	-271	-157	-156	N/A
3/31/2021	9	-266	-327	-326	N/A
12/31/2020	9	-248	-323	-322	N/A
9/30/2020	8	-369	-427	-427	N/A
6/30/2020	15	-343	-428	-427	N/A
3/31/2020	20	-310	-265	-264	N/A
12/31/2019	27	-290	-254	-251	N/A
9/30/2019	32	-129	-142	-139	N/A
6/30/2019	30	-120	-98	-96	N/A
3/31/2019	29	-114	-90	-88	N/A
12/31/2018	54	-81	-84	-84	N/A
9/30/2018	55	-72	-72	-71	N/A
6/30/2018	62	-53	-94	-93	N/A
3/31/2018	67	-36	-86	-85	N/A
12/31/2017	48	-48	-84	-83	N/A
9/30/2017	50	-35	-70	-70	N/A
6/30/2017	50	-24	-47	-47	N/A
3/31/2017	50	-13	N/A	-42	N/A
12/31/2016	50	-6	N/A	-19	N/A
9/30/2016	50	-4	N/A	-21	N/A
6/30/2016	50	-2	N/A	-35	N/A
3/31/2016	50	-3	N/A	-35	N/A
12/31/2015	50	-1	N/A	-45	N/A
9/30/2015	50	0	N/A	-42	N/A
6/30/2015	51	0	N/A	-42	N/A
3/31/2015	51	2	N/A	-63	N/A
12/31/2014	51	1	N/A	-89	N/A
12/31/2013	51	-36	N/A	-69	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RETA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: RETA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RETA is expected to become profitable in the next 3 years.

Revenue vs Market: RETA's revenue (48.1% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: RETA's revenue (48.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RETA's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Reata Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 60%

Consensus revenue estimates increase by 67%

Price target increased by 8.5% to US$125

Consensus revenue estimates increase by 27%, EPS downgraded

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Recent updates

Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from NASDAQ Composite Index

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Insider recently sold US$546k worth of stock

Insider notifies of intention to sell stock

Executive VP & Chief Innovation Officer recently sold US$463k worth of stock

Sanofi Reportedly Second Bidder for Reata

Consensus revenue estimates increase by 60%

Consensus revenue estimates increase by 67%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

COO, CFO & President notifies of intention to sell stock

New major risk - Share price stability

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Price target increased by 8.5% to US$125

Reata Pharmaceuticals, Inc. Announces Approval of Prior Approval Supplement for SKYCLARYS®? (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia

Reata Pharmaceuticals, Inc.(NasdaqGM:RETA) dropped from Russell 2000 Growth Index

COO, CFO & President recently sold US$6.0m worth of stock

COO, CFO & President notifies of intention to sell stock

Reata Pharmaceuticals Appoints Rajiv Patni as Executive Vice President, Chief Research & Development Officer

Insider recently sold US$616k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Forecast to breakeven in 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Executive VP & Chief Commercial Officer recently sold US$808k worth of stock

Executive VP & Chief Commercial Officer recently sold US$630k worth of stock

Executive VP & Chief Innovation Officer exercised options and sold US$7.7m worth of stock

Forecast to breakeven in 2025

Consensus revenue estimates increase by 18%, EPS downgraded

Price target increased by 75% to US$104

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$59.50

Consensus forecasts updated

Price target increased to US$59.50

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Reata Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug

Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to US$50.67

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Reata Pharmaceuticals Q2 2022 Earnings Preview

Reata Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Reata Pharmaceuticals, Inc. Announces the Appointment of Steven W. Ryder, M.D. to Board of Directors

We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth

Reata Pharmaceuticals, Inc. Announces Retirement of Jack B. Nielsen from Board of Directors

Reata Pharmaceuticals Announces U.S. Food and Drug Administration Filing Acceptance

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Reata Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Reata Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2022

Price target increased to US$59.67

Reata Pharmaceuticals Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

Reata Pharmaceuticals: Once Beaten, Twice Shy

Price target increased to US$62.75

Reata Pharmaceuticals, Inc. Notifies Jack B. Nielsen's Intention to Retire from the Board

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Reata Pharmaceuticals Receives Complete Response Letter from the FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Reata Pharmaceuticals, Inc. Announces Executive Changes

Pomerantz LLP Files Class Action Lawsuit Against Reata Pharmaceuticals, Inc

Block & Leviton LLP Files Class Action Lawsuit Against Reata Pharmaceuticals, Inc. for Securities Fraud, Expanding the Class Period

Reata's Advisory Committee Hiccup Ruins Its Future Prospects

Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts